Topotecan Hydrochloride

Danger

H300 (37.5%): Fatal if swallowed [Danger Acute toxicity, oral]；H301 (12.5%): Toxic if swallowed [Danger Acute toxicity, oral]；H302 (12.5%): Harmful if swallowed [Warning Acute toxicity, oral]；H315 (12.5%): Causes skin irritation [Warning Skin corrosion/irritation]；H319 (12.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H335 (12.5%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]；H340 (87.5%): May cause genetic defects [Danger Germ cell mutagenicity]；H350 (50%): May cause cancer [Danger Carcinogenicity]；H351 (25%): Suspected of causing cancer [Warning Carcinogenicity]；H360 (37.5%): May damage fertility or the unborn child [Danger Reproductive toxicity]；H360D (12.5%): May damage the unborn child [Danger Reproductive toxicity]；H361 (25%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]；H370 (25%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]；H412 (37.5%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P308+P316, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 8 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Acute Tox. 2 (37.5%)；Acute Tox. 3 (12.5%)；Acute Tox. 4 (12.5%)；Skin Irrit. 2 (12.5%)；Eye Irrit. 2 (12.5%)；STOT SE 3 (12.5%)；Muta. 1B (87.5%)；Carc. 1B (50%)；Carc. 2 (25%)；Repr. 1B (37.5%)；Repr. 2 (25%)；STOT SE 1 (25%)；Aquatic Chronic 3 (37.5%)

Drug Induced Liver Injury Rank (DILIrank 2.0)

Topotecan hydrochloride

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

◉ Summary of Use during Lactation；Most sources consider breastfeeding to be contraindicated during maternal high-dose antineoplastic drug therapy. The manufacturer recommends that women not breastfeed during treatment with topotecan and for 1 week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.

TOPOTECAN HYDROCHLORIDE

Topoisomerase Inhibitor [EPC]; Topoisomerase Inhibitors [MoA]